Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured from a Genetically Engineered Strain of Measles Virus in Patients with Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor

NCT02700230 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02700230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02700230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured from a Genetically Engineered Strain of Measles Virus in Patients with Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
March 22, 2017
Completion date
April 17, 2024
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant peripheral nerve sheath tumor, neurofibromatosis type 1, recurrent malignant peripheral nerve sheath tumor